Advances and Advocacy in the Treatment of Acute Ischemic Stroke (Health Care Forum)

Advances and Advocacy in the Treatment of Acute Ischemic Stroke (Health Care Forum)

Since its approval in 1995, intravenous recombinant tissue plasminogen activator (IV rt-PA) remains the only FDA-sanctioned therapy for acute, ischemic strokes in the United States (Leira & Adams, 2004). The initial, government-sponsored study (National Institute of Neurological Disorders and Stroke [NINDS], 1995) found that stroke victims treated with IV rt-PA were twice as likely to have a good outcome as those who were not. Moreover, a recent reanalysis of the data determined that the drug’s side effects are smaller and its benefits greater than were originally found (Marchione, 2005). However, a decade later, less than 3% of stroke victims who may be candidates for thrombolysis (i.e., breaking up of a blood clot) actually receive the drug (Biller & Fernandez-Beer, 2004). In this forum, barriers to the widespread use of IV rt-PA, as well as future possibilities for improved thrombolytic therapy, are reviewed. BARRIERS TO APPROPRIATE ADMINISTRATION OF CURRENT THROMBOLYTIC THERAPY

Advances and Advocacy in the Treatment of Acute Ischemic Stroke (Health Care Forum)

Advances and Advocacy in the Treatment of Acute Ischemic Stroke (Health Care Forum) | | 4.5